The National Institutes of Health has paused a major human trial of an experimental drug for stroke protection. Lack of coverage for fertility services is a challenge for those interested in Casgevy or a second sickle cell cure. Multiple HIV vaccine trials, including PrEPVacc, have been halted due to disappointing results, including a study in Africa billed as the last chance to develop an HIV vaccine this decade.
HIV vaccine trial in Africa halted after disappointing data https://t.co/0DlCEyI0yf https://t.co/Ih8niu5d7A
A study billed as the last chance to develop an HIV vaccine this decade has been shut down. https://t.co/saTtXI0Bj5
HIV vaccine trial in Africa halted after disappointing initial results https://t.co/wrhPZdczKv
PrEPVacc was one of the first large, African-led HIV vaccine trials and one of the first trials to incorporate PrEP. Now it's shutting down, and no other vaccine trials are… https://t.co/yuemDxVMeD
In January I reported for @NBCNews on yet another failure of a major HIV vaccine trial. At the time, I noted that 1 major trial was ongoing. Today, that trial's leaders announced it "has stopped further vaccinations as there is little or no chance of the trial demonstrating… https://t.co/d1FmwnmxCQ
Lack of coverage for fertility services will be a huge obstacle for people eager to try Casgevy or a second sickle cell cure awaiting U.S. approval. https://t.co/MjboxH5BMu
The National Institutes of Health has paused the start of a major human trial of an experimental drug aimed at protecting the brain after stroke. https://t.co/7ZUUotrb4H